S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
NASDAQ:SRGA

Surgalign Stock Forecast, Price & News

$0.77
+0.03 (+4.04%)
(As of 12/7/2021 04:00 PM ET)
Add
Compare
Today's Range
$0.74
$0.81
50-Day Range
$0.73
$1.14
52-Week Range
$0.70
$3.27
Volume
1.55 million shs
Average Volume
2.87 million shs
Market Capitalization
$107.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.1
30 days | 90 days | 365 days | Advanced Chart
Receive SRGA News and Ratings via Email

Sign-up to receive the latest news and ratings for Surgalign and its competitors with MarketBeat's FREE daily newsletter.


Surgalign logo

About Surgalign

Surgalign Holdings, Inc. is a medical technology company, which engages in designing, developing, and manufacturing biologic metal and synthetic implants. Its products portfolio include cervical fixation, The Streamline (TL) fixation, motion preservation, orthobiologics, cervical inter-body fusion, TL IBF, and SI joint fusion. It offers coflex interlaminar stabilization device, SImmetry sacroiliac joint fusion system, and Fortilink IBF system with TETRAfuse?3D technology. The company was founded on February 12, 1998 and is headquartered in Deerfield, IL.

Headlines

Surgalign Holdings, Inc. (NASDAQ:SRGA) Short Interest Update
December 1, 2021 |  americanbankingnews.com
Surgalign Holdings: The Saga Continues - Seeking Alpha
November 12, 2021 |  seekingalpha.com
Surgalign Q3 2021 Earnings Preview - Seeking Alpha
November 11, 2021 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRGA
Employees
197
Year Founded
N/A

Sales & Book Value

Annual Sales
$101.75 million
Book Value
$0.34 per share

Profitability

Net Income
$-33.78 million
Net Margins
-146.88%
Pretax Margin
-161.51%

Debt

Price-To-Earnings

Miscellaneous

Free Float
123,889,000
Market Cap
$107.46 million
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
12/07/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/15/2022

MarketRank

Overall MarketRank

1.88 out of 5 stars

Medical Sector

752nd out of 1,394 stocks

Surgical Appliances & Supplies Industry

17th out of 27 stocks

Analyst Opinion: 3.4Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Surgalign (NASDAQ:SRGA) Frequently Asked Questions

Is Surgalign a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Surgalign in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Surgalign stock.
View analyst ratings for Surgalign
or view top-rated stocks.

Are investors shorting Surgalign?

Surgalign saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 3,680,000 shares, a decrease of 33.5% from the October 31st total of 5,530,000 shares. Based on an average daily volume of 2,710,000 shares, the days-to-cover ratio is currently 1.4 days.
View Surgalign's Short Interest
.

When is Surgalign's next earnings date?

Surgalign is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Surgalign
.

How were Surgalign's earnings last quarter?

Surgalign Holdings, Inc. (NASDAQ:SRGA) released its earnings results on Tuesday, November, 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.03. The business had revenue of $20.55 million for the quarter, compared to the consensus estimate of $22.55 million. Surgalign had a negative net margin of 146.88% and a negative trailing twelve-month return on equity of 128.61%. During the same period last year, the firm posted ($0.11) EPS.
View Surgalign's earnings history
.

What guidance has Surgalign issued on next quarter's earnings?

Surgalign issued an update on its FY 2021 earnings guidance on Tuesday, December, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $88 million-$92 million, compared to the consensus revenue estimate of $96.05 million.

What price target have analysts set for SRGA?

5 equities research analysts have issued 1 year price objectives for Surgalign's shares. Their forecasts range from $1.50 to $4.00. On average, they expect Surgalign's stock price to reach $3.15 in the next twelve months. This suggests a possible upside of 308.0% from the stock's current price.
View analysts' price targets for Surgalign
or view top-rated stocks among Wall Street analysts.

Who are Surgalign's key executives?

Surgalign's management team includes the following people:
  • Terry M. Rich, President, Chief Executive Officer & Director (LinkedIn Profile)
  • G. Bryan Cornwall, EVP-Research & Clinical Affairs
  • Douglas S. Bireley, Executive VP-Marketing, Research & Development
  • Bob Watkins, Chief Information & Technology Officer
  • Chris Thunander, Chief Accounting Officer & Vice President

What is Surgalign's stock symbol?

Surgalign trades on the NASDAQ under the ticker symbol "SRGA."

Who are Surgalign's major shareholders?

Surgalign's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Krensavage Asset Management LLC (4.55%), Eversept Partners LP (2.52%), Dimensional Fund Advisors LP (2.49%), Assenagon Asset Management S.A. (2.03%), Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (1.34%) and Morgan Stanley (0.98%). Company insiders that own Surgalign stock include Mark Stolper, Nicholas J Valeriani, Terry M Rich, Thomas Mceachin and William Scott Durall.
View institutional ownership trends for Surgalign
.

Which major investors are selling Surgalign stock?

SRGA stock was sold by a variety of institutional investors in the last quarter, including TownSquare Capital LLC, Millennium Management LLC, Morgan Stanley, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Eversept Partners LP, Mitsubishi UFJ Kokusai Asset Management Co. Ltd., and Verition Fund Management LLC.
View insider buying and selling activity for Surgalign
or view top insider-selling stocks.

Which major investors are buying Surgalign stock?

SRGA stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Fuller & Thaler Asset Management Inc., Two Sigma Investments LP, UBS Group AG, Dfpg Investments LLC, Two Sigma Advisers LP, Geode Capital Management LLC, and HighTower Advisors LLC. Company insiders that have bought Surgalign stock in the last two years include Mark Stolper, Nicholas J Valeriani, Terry M Rich, Thomas Mceachin, and William Scott Durall.
View insider buying and selling activity for Surgalign
or or view top insider-buying stocks.

How do I buy shares of Surgalign?

Shares of SRGA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surgalign's stock price today?

One share of SRGA stock can currently be purchased for approximately $0.77.

How much money does Surgalign make?

Surgalign has a market capitalization of $107.46 million and generates $101.75 million in revenue each year. The company earns $-33.78 million in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Surgalign have?

Surgalign employs 197 workers across the globe.

What is Surgalign's official website?

The official website for Surgalign is www.surgalign.com.

Where are Surgalign's headquarters?

Surgalign is headquartered at 520 LAKE COOK ROAD SUITE 315, DEERFIELD IL, 60015.

How can I contact Surgalign?

Surgalign's mailing address is 520 LAKE COOK ROAD SUITE 315, DEERFIELD IL, 60015. The company can be reached via phone at (224) 303-4651, via email at [email protected], or via fax at 386-418-0342.


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.